Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

38.58 -0.49 (-1.25%)
Official Closing Price Updated: 4:10 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,152,830
Open 38.58
Bid (Size) 38.44 (900)
Ask (Size) 38.45 (100)
Prev. Close 39.07
Today's Range 38.16 - 38.85
52wk Range 35.85 - 91.90
Shares Outstanding N/A
Dividend Yield 3.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors ↗
Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations. 
Via The Motley Fool
News headline image
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a... 
Via MarketMinute
Topics Economy Intellectual Property Lawsuit

Performance

YTD
-26.4%
-26.4%
1 Month
-23.3%
-23.3%
3 Month
-19.6%
-19.6%
6 Month
-31.3%
-31.3%
1 Year
-57.5%
-57.5%

More News

Read More
News headline image
Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again ↗
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Unexpected Stock Picks and Looking to the Future ↗
Via The Motley Fool
News headline image
Why I'm Not Worried About Novo Nordisk Stock ↗
Via The Motley Fool
Topics Intellectual Property
MarketBeat Week in Review – 02/23 - 02/27 ↗
Via MarketBeat
News headline image
The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
Via MarketMinute
Topics Artificial Intelligence ETFs
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗
Via The Motley Fool
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
Via The Motley Fool
News headline image
Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗
Via The Motley Fool
News headline image
Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
Via MarketBeat
News headline image
The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗
Via The Motley Fool
News headline image
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗
Via The Motley Fool
Topics Stocks
News headline image
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗
Via The Motley Fool
News headline image
1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗
Via The Motley Fool
Topics Economy
News headline image
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗
Via Stocktwits
News headline image
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 ↗
Via Benzinga
News headline image
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗
Via The Motley Fool

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 38.58
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 03/06/26 04:10 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.